Tirzepatide at the highest doses (15 mg) may be associated with slightly more GI side effects, which makes sense given its additional GIP receptor activity
Dose Optimization & Microdosing Instead of stopping suddenly, we reduce dosage in small, controlled increments
44,45 In a meta-analysis of 48 RCTs including 27,729 participants, the overall incidence of GI adverse events was reported to be 11.6%, with nausea identified as the most common symptom (21.4%)
Kramer CM, Borlaug BA, Zile MM, et al
Our goal was to create an accessible, science-backed system that fills essential nutrient gaps, while also helping individuals feel their best throughout their weight-loss journey by addressing nutrition-related issues that are associated with GLP-1 drugs.